| |
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
Today’s Big NewsJan 10, 2025 |
|
The U.S. Department of Veterans Affairs (VA) is at the forefront of healthcare innovation, developing cutting-edge technologies to improve the lives of veterans . Now, your business can leverage these advancements. Download today to learn more! 
|
|
| By Angus Liu The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire from the agency. |
|
|
|
By Darren Incorvaia A new company is making its debut with a series A sum that’s sure to make hearts race. Launching with $300 million in hand, Kardigan plans to develop parallel treatments to prevent and cure cardiovascular diseases so that they’re no longer the leading cause of death worldwide, the company announced in a Jan. 10 release. |
By Conor Hale Their second exclusive, global in-licensing covers a second small molecule inhibitor, this time targeting what they described as a variety of solid tumors. |
By Kevin Dunleavy Why is Big Pharma suddenly placing bets—big and small—on a medicine type that has been in the works for nearly a century? And where is the industry headed with the development of radiopharmaceuticals in 2025? |
|
As the market for complex biologics continues to grow, effective capacity planning becomes more challenging. The entry of the 5,000L single-use bioreactor (SUB) is providing an important bridge between small-scale and large-scale production, offering more flexibility than ever before to respond to fluctuations in demand quickly and efficiently. Access this report to learn more. 
|
|
By Fraiser Kansteiner Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. Late this week, a quartet of companies—IGM Biosciences, Y-mAbs Therapeutics, Passage Bio and Shoreline Biosciences—each revealed plans to cut jobs as they rework their respective pipelines and business structures. |
By Conor Hale Illumina has begun shipping a single-flow cell system for its NovaSeq X series, to offer a more accessible price point for smaller labs. |
By Kevin Dunleavy For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site, 10 hours to the south in Hyderabad. |
By Gabrielle Masson 4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be pivoted toward launching late-stage studies for the biotech's eye disease gene therapy 4D-150. |
By Angus Liu On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. |
By Zoey Becker Lilly and venture capital fund a16z are joining forces to create the Biotech Ecosystem Venture Fund, backed by $500 million of Lilly's capital. |
By Nick Paul Taylor Matt McNally is rejoining Publicis. The ad exec has taken the global CEO post at Publicis Health, returning to a company where he spent 14 years prior to a recent detour that took in the top job at Omnicom Health Group. |
By Darren Incorvaia The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
|
With unique perspectives from key opinion leaders, this whitepaper examines the challenges associated with process development and manufacturing of cell and gene therapies. Download now to take your cell and gene therapy techniques to new heights. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
